Immunology and Immunotherapy of Head and Neck Cancer.

By R. Ferris. Journal of Clinical Oncology, 2015

602 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Otorhinolaryngology

View Paper: https://www.semanticscholar.org/paper/e93882287f65cf70b949635a1264bad84097bf88

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. El-Deiry
2. K. Higgins
3. C. Steuer
4. N. Saba
5. J. Parks

Citations in the corpus

• An update on larynx cancer (2017, background): “However, toxicity was higher with induction therapy, with 52 serious adverse events versus 22 in the CRT arm.80 Given the high risk of recurrence in patients with advanced SCCHN and the potential benefits of induction therapy, the DeCIDE trial (docetaxel-based CRT with or without induction chemother”
• Unraveling the Role of Tumor-Infiltrating Immune Cells in Head and Neck Squamous Cell Carcinoma: Implications for Antitumor Immune Responses and Immunotherapy (2025, unknown): “Both the absence of immune cells and the presence of functionally impaired effector cells, such as NK cells or cytotoxic CD8+ cells, have been reported, as well as the presence of immunosuppressive cells, including TAMs, MDSCs, and Tregs and Bregs [54].”